Bluebird business account #blue, #blue #analyst #estimates, #blue #earnings #estimates, #blue #share #estimates, #blue #analyst


#

bluebird bio Inc.

U.S. stocks are mixed early Wednesday, treading water ahead of the Federal Reserve s policy directive, due out this afternoon. Against this backdrop, the Dow industrials slow-motion breakout attempt remains underway, while the Nasdaq Composite continues to digest its striking mid-June downdraft.

  • Jun. 14, 2017 at 11:23 a.m. ET
  • by Michael Ashbaugh
  • Jun. 8, 2017 at 7:46 a.m. ET
  • by Emma Court

Bluebird Bio stock fair value estimate raised to $125 from $81 at Janney

Bluebird Bio stock fair value estimate raised to $125 from $81 at Janney

  • Jun. 7, 2017 at 7:15 a.m. ET
  • by Tomi Kilgore
  • Jun. 6, 2017 at 12:41 p.m. ET
  • by Harry Boxer

Bluebird Bio stock price target raised to $108 from $83 at BMO Capital

Bluebird Bio stock price target raised to $108 from $83 at BMO Capital

  • Jun. 6, 2017 at 9:17 a.m. ET
  • by Tomi Kilgore

Bluebird Bio upgraded to outperform from market perform at BMO Capital

Bluebird Bio upgraded to outperform from market perform at BMO Capital

  • Jun. 6, 2017 at 9:16 a.m. ET
  • by Tomi Kilgore

Bluebird Bio Inc. shares rose 7.4% in heavy morning trade Monday after the company released updated results from an ongoing early-stage clinical trial in relapsed/refractory multiple myeloma. Relapsed multiple myeloma refers to when the cancer returns after treatment, while refractory multiple myeloma means the cancer isn t responding to treatment. The drug, bb2121, which is being jointly developed by Bluebird Bio and Celgene Corp. had a 100% overall response rate in three of four groups of dosed patients, with the other group having an overall response rate of 33%. The 31 patients who were enrolled in the trial as of early May (the company plans to enroll up to 50 patients total) got several types of treatment prior to bb2121, with a median of 7 lines of prior therapy, with the range varying between three and 14 lines of therapy, the company said. None of the patients in the active dose groups saw the cancer progress, said Celgene s Michael Pehl, president, hematology and oncology. The consistency, depth and durability of these patients responses coupled with a manageable safety profile is very exciting, and we believe will provide hope for patients in this setting, Pehl said. The efficacy and safety profile of bb2121 continues to look very strong, said Leerink analyst Michael Schmidt. We believe these data position BLUE (and partner CELG [MP]) well among companies developing CAR-T products in multiple myeloma and provide additional validation for bb2121 and BLUE s emerging CAR-T platform, referring to CAR-T cell therapy, a type of cancer immunotherapy that uses a patient s blood cells to fight cancer. Bluebird Bio shares have risen 7% to $91.45 over the last three months, compared with a 2.2% rise in the S P 500.

  • Jun. 5, 2017 at 9:46 a.m. ET
  • by Emma Court

Bluebird Bio stock rises 7% on positive data from ongoing early-stage clinical trial

Bluebird Bio stock rises 7% on positive data from ongoing early-stage clinical trial

  • Jun. 5, 2017 at 9:18 a.m. ET
  • by Emma Court

Bluebird Bio Inc. shares jumped 7.3% in premarket trade Friday after the company was upgraded to buy from hold at Maxim Group, with a price target of $100, above the company s $79.20 share price as of Thursday s close. The American Society of Clinical Oncology meeting, which begins Friday and runs through Tuesday, could be a big opportunity for the company s shares, with the company scheduled to present data on multiple myeloma, said Maxim Group analyst Jason Kolbert. Kolbert said he believes positive data from December for Bluebird Bio s bb2121 — which is being developed in partnership with Celgene Corp. — along with positive results for the same type of cancer approach in May from another biotech company, increase the probability for positive data for bb2121 at ASCO. Bluebird Bio is scheduled to present safety and efficacy data from a trial enrolling 18 patients on Monday, with the results including one-year follow-up data for the first nine patients. Bluebird Bio shares have dropped 9% over the last three months, compared with a 2% rise in the S P 500.

  • Jun. 2, 2017 at 8:15 a.m. ET
  • by Emma Court

Bluebird Bio shares jump 7% premarket

Bluebird Bio shares jump 7% premarket

  • Jun. 2, 2017 at 7:59 a.m. ET
  • by Ciara Linnane

Celgene (CELG) and Bluebird Bio (BLUE) stocks sustained downgrades Friday as rivals like Kite Pharma (KITE) and Juno Therapeutics (JUNO) look likely to chip away at their lead in immuno-oncology drugs. The duo is about a year ahead with a drug called bb2121, part of a class of treatments that aim to reprogram the immune system to fight cancer using what are known as CAR-T therapies. Their drug does this by targeting an antigen called BCMA. But

  • Jun. 30, 2017 at 2:54 p.m. ET
  • on Investors Business Daily

Bluebird bio downgraded at BTIG as abundance of good news priced in

  • Jun. 30, 2017 at 2:48 p.m. ET
  • on Seeking Alpha

Imagine being told you have cancer, and have six months to live. The usual steps are taken one or two rounds of chemotherapy, perhaps a stem-cell transplant but all of it could be to no avail. Half of all patients diagnosed with aggressive non-Hodgkin lymphoma, a form of blood cancer, will die within six months, says Christine Cassiano, spokeswoman for Kite Pharma (KITE), a developer of cancer treatments. [ibd-display-video id=1316712 width=50

  • Jun. 30, 2017 at 12:10 p.m. ET
  • on Investors Business Daily

After Bluebird s 75% Gain In 2017, Analysts At BTIG Downgrade To Neutral

  • Jun. 30, 2017 at 7:50 a.m. ET
  • on benzinga.com

Cara Therapeutics (CARA) stock launched to a nearly two-year high Friday after its chronic liver disease drug grabbed breakthrough designation beating the odds at the Food and Drug Administration. In midday trading at the stock market today, Cara stock popped 8.8%, near 21.60, after earlier rising as much as 18.5%, touching a high last seen in August 2015. Shares broke out of a cup-with-handle pattern Wednesday after hitting an 18.93 buy point.

  • Jun. 23, 2017 at 1:24 p.m. ET
  • on Investors Business Daily

[ibd-display-video id=1018553 top=true]With biotech stocks like Celgene (CELG), Bluebird Bio (BLUE), Regeneron (REGN) and Biogen (BIIB) spinoff Bioverativ (BIVV) on the move, cancer drug developer Exelixis (EXEL) may be on track for a new breakout. Boosted by FDA approval for its cabozantinib kidney cancer drug in April 2016, Exelexis has seen average revenue growth of 497% over the last four quarters. Cabozantinib generated $68.9 million in Q1, a

  • Jun. 23, 2017 at 10:32 a.m. ET
  • on Investors Business Daily

Biotech stocks reversed course Friday after a five-day run to a 17-month high with Regeneron Pharmaceuticals (REGN) and Bluebird Bio (BLUE) among those losing the most, though Cara Therapeutics (CARA) defied the trend. [ibd-display-video id=1000287 width=50 float=left]In early trading on the stock market today, Bluebird Bio stock toppled 5.7%, near 111.80, with shares of Regeneron trailing, down 3.3%, near 509.30. The duo had been big winners in

  • Jun. 23, 2017 at 10:33 a.m. ET
  • on Investors Business Daily

bluebird bio Announces Pricing of Public Offering of Common Stock

  • Jun. 27, 2017 at 6:29 p.m. ET
  • on BusinessWire – BZX

Leave a Comment

Your email address will not be published. Required fields are marked *